

Regimen Reference Order

LYMP – etoposide + vinBLASTine + bleomycin + dacarbazine (EBVD)

ARIA: LYMP – [EBVD]

Planned Course: Every 28 days for 6 cycles

Indication for Use: Hodgkin Lymphoma

CVAD: At Provider's Discretion (VESICANT INVOLVED)

Proceed with treatment if:

Day 1

- Patient is feeling well (no signs or symptoms of infection)
- Contact Hematologist if ANC less than $0.8 \times 10^9/L$ OR Platelets less than $100 \times 10^9/L$
 - ❖ DO NOT DELAY OR CANCEL THERAPY WITHOUT CONSULTING HEMATOLOGIST

Day 15

- Patient is feeling well (no signs or symptoms of infection)
- No CBC is required for Day 15 treatment
 - ❖ DO NOT DELAY OR CANCEL THERAPY WITHOUT CONSULTING HEMATOLOGIST

Note: Asymptomatic patients are not usually delayed for neutropenia regardless if ANC parameters are met. If the hematologist delays treatment, direction to be provided by the hematologist on management of neutropenia and length of delay

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
allopurinol*	300 mg	Orally once daily for 10 days to begin 3 days prior to Cycle 1 and at provider's discretion for subsequent cycles (Self-administered at home) *Only patients at risk of tumor lysis syndrome will be prescribed allopurinol

Treatment Regimen – LYMP – etoposide + vinBLASTine + bleomycin + dacarbazine (EBVD)

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
Days 1 and 15		
aprepitant	125 mg	Orally 1 hour pre-chemotherapy
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy

etoposide	25 mg/m ²	IV in normal saline 250 mL over 1 hour <i>Use non-DEHP bags and non-DEHP administration sets</i> <i>Concentration dependent drug: Pharmacy will adjust diluent volume to ensure drug stability</i>
vinBLAStine	6 mg/m ²	IV in normal saline 25 mL over 5 to 10 minutes by gravity infusion
hydrocortisone	100 mg	ONLY to be given if patient experienced fever and/or chills with any previous administration of bleomycin IV push over 1 minute if indicated prior to all subsequent bleomycin doses
bleomycin	10 units/m ²	IV in normal saline 50 mL over 10 minutes
dacarbazine	375 mg/m ²	IV in D5W 500 mL over 2 hours <i>Concentration dependent drug: Pharmacy will adjust diluent volume to ensure drug stability</i>
Days 2, 3, 16 and 17		
etoposide	50 mg/m ² (to nearest 50 mg)	Orally once daily in the morning on an empty stomach Swallow whole (Self-administered at home)
etoposide (VePesid®) available dosage strength: 50 mg capsule Classification: Cytotoxic, Hazardous		

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

All Cycles

Day 1

- CBC, serum creatinine, urea, electrolytes, liver enzymes, LDH, total bilirubin, uric acid and albumin as per Physician Orders

Day 15

- No blood work required

Pulmonary Function Tests (PFTs)

- Pulmonary function monitoring as clinically indicated as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
aprepitant	80 mg	Orally once daily on Days 2, 3, 16 and 17
dexamethasone	8 mg	Orally once daily on Days 2, 3, 16 and 17
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to continue taking anti-emetic(s) at home
- Nurse will provide oral etoposide to the patient on Day 1 and Day 15. Remind patient to take etoposide at home
- Patients should notify clinic prior to starting any new medication. etoposide has potential for drug-drug interactions
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- bleomycin is associated with pulmonary toxicity
- For patients who do not tolerate oral etoposide, it may be substituted with intravenous etoposide at the physician's discretion. Intravenous etoposide dose would be 25 mg/m² on Days 2, 3, 16 and 17 for this regimen
- Oral etoposide is dispensed by CCMB Pharmacy to nursing (treatment room) on Day 1 and Day 15. CCMB Pharmacy will ship oral etoposide to CCP Pharmacy for patients being treated at a CCP